Hemophilia B replacement therapy drugs.
- Author:
Hong YAN
;
Fanyi ZENG
- Publication Type:Journal Article
- MeSH:
Factor IX;
genetics;
therapeutic use;
Hemophilia B;
drug therapy;
Humans;
Mutation;
Recombinant Proteins;
therapeutic use
- From:Chinese Journal of Biotechnology
2016;32(2):164-171
- CountryChina
- Language:Chinese
-
Abstract:
Hemophilia B is an X chromosome linked hereditary hemorrhagic disease, which is caused by the lose function mutation of factor IX (FIX), and significantly affects the patients' lifespan and life quality. The severity of hemophilia B depends on the FIX level in the plasma. By referring to the relevant literatures, we reviewed and summarized hemophilia B replacement therapies. Specifically, we focus on recombinant factor IX products on the market and those in the pipeline, especially on the long-acting factor IX drugs, to provide the basis for researches of new hemophilia B drugs.
